Paul, Hastings, Janofsky & Walker LLP, a leading global law firm, is pleased to announce that it has advised Cell Signaling Technology, Inc. (CST), a leader in the development and manufacturing of high performance antibody products for the medical research and clinical diagnostic markets, in its joint commercialization partnership with Japan’s Astellas Pharma, Inc. (Astellas).
Under this agreement, CST and Astellas have combined their intellectual property estates relating to the fusion kinase, EML4-ALK, to enable the commercialization of diagnostic and therapeutic products targeting this cancer enzyme. The partnership provides each party with the right to exploit joint intellectual property estates and will encourage the development of products targeting EML4-ALK.
Related Posts:
- None Found